Biotech Values

[jq1234]

In light of NVS purchase of GSK oncology portfolio, I'd change company D in ONXX SEC filing to GSK rather than PFE:

GSK will divest its marketed Oncology portfolio, related R&D activities and rights to its AKT inhibitor and also grant of commercialisation partner rights for future oncology products to Novartis for an aggregate cash consideration of $16 billion (of which up to $1.5 billion depends on the results of the COMBI-d trial)

http://www.gsk.com/media/press-releases/2014/gsk-announces-major-three-part-transaction-with-novartis.html